Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

831 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K. Kumada H, et al. Among authors: enomoto n. J Gastroenterol. 2018 Apr;53(4):566-575. doi: 10.1007/s00535-017-1396-0. Epub 2017 Oct 20. J Gastroenterol. 2018. PMID: 29052790 Free PMC article. Clinical Trial.
Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy.
Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, Ueda E, Tanabe Y, Maekawa S, Itakura J, Watanabe H, Kakinuma S, Watanabe M. Hamano K, et al. Among authors: enomoto n. J Gastroenterol Hepatol. 2005 Sep;20(9):1401-9. doi: 10.1111/j.1440-1746.2005.04024.x. J Gastroenterol Hepatol. 2005. PMID: 16105128
Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response.
Asahina Y, Izumi N, Hirayama I, Tanaka T, Sato M, Yasui Y, Komatsu N, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Tasaka M, Sakamoto N, Miyake S. Asahina Y, et al. Among authors: enomoto n. Gastroenterology. 2008 May;134(5):1396-405. doi: 10.1053/j.gastro.2008.02.019. Epub 2008 Feb 14. Gastroenterology. 2008. PMID: 18471516
Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.
Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M; PERFECT Study Group. Watanabe S, et al. Among authors: enomoto n. Hepatol Res. 2010 Feb;40(2):135-44. doi: 10.1111/j.1872-034X.2009.00567.x. Epub 2009 Sep 25. Hepatol Res. 2010. PMID: 19788694
Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.
Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, Itsui Y, Tasaka-Fujita M, Onuki-Karakama Y, Suda G, Mishima K, Yamamoto M, Ueyama M, Funaoka Y, Watanabe T, Azuma S, Sekine-Osajima Y, Kakinuma S, Tsuchiya K, Enomoto N, Tanaka H, Watanabe M. Nishimura-Sakurai Y, et al. Among authors: enomoto n. J Gastroenterol. 2010 May;45(5):523-36. doi: 10.1007/s00535-009-0162-3. Epub 2009 Dec 12. J Gastroenterol. 2010. PMID: 20012654
Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
Nakagawa M, Sakamoto N, Ueyama M, Mogushi K, Nagaie S, Itsui Y, Azuma S, Kakinuma S, Tanaka H, Enomoto N, Watanabe M. Nakagawa M, et al. Among authors: enomoto n. J Gastroenterol. 2010 Jun;45(6):656-65. doi: 10.1007/s00535-009-0195-7. Epub 2010 Jan 30. J Gastroenterol. 2010. PMID: 20112032
831 results